Broncus Holding Dividendos y recompras

Dividendo controles de criterios 0/6

Broncus Holding no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

Rendimiento de la recompra

Rendimiento total para el accionista	0%
Rendimiento futuro de los dividendos	0%
Crecimiento de los dividendos	n/a
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Ratio de pago	n/a

Últimas actualizaciones de dividendos y recompras

No hay actualizaciones

Recent updates

An Intrinsic Calculation For Broncus Holding Corporation (HKG:2216) Suggests It's 47% Undervalued

Dec 06

Analysts Just Slashed Their Broncus Holding Corporation (HKG:2216) EPS Numbers

Sep 04

Here's Why We're Not Too Worried About Broncus Holding's (HKG:2216) Cash Burn Situation

Jun 21

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de 2216 han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de 2216 han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Broncus Holding vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de 2216 con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (2216)	n/a
Suelo de mercado 25% (HK)	3.3%
Techo de mercado 25% (HK)	8.1%
Media de la industria (Medical Equipment)	3.4%
Analista de previsiones (2216) (hasta 3 años)	0%

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de 2216 en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de 2216 en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de 2216 para determinar si sus pagos de dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que 2216 no ha comunicado ningún pago.

Broncus Holding Dividendos y recompras

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos y recompras

Recent updates

First half 2024 earnings released: US$0.016 loss per share (vs US$0.03 loss in 1H 2023)

Broncus Holding Corporation to Report Q2, 2024 Results on Aug 29, 2024

Broncus Holding Corporation Announces Management Changes

Broncus Holding Corporation Announces Changes to Its Board

Full year 2023 earnings: EPS and revenues miss analyst expectations

Broncus Holding Corporation, Annual General Meeting, May 20, 2024

We Think Broncus Holding (HKG:2216) Needs To Drive Business Growth Carefully

Broncus Holding Corporation to Report Fiscal Year 2023 Results on Mar 28, 2024

Broncus Holding Corporation Announces Resignation of Zhenjun Zi as Non-Executive Director

Broncus Holding (HKG:2216) Is In A Good Position To Deliver On Growth Plans

Broncus Holding Corporation (SEHK:2216) entered into share purchase agreement to acquire Fibernova Holding Corporation from from Zhao and others for $2.7 million.

First half 2023 earnings released: US$0.03 loss per share (vs US$0.033 loss in 1H 2022)

Broncus Holding Corporation Announces Chief Executive Officer Changes, Effective on September 1, 2023

Broncus Holding Corporation Announces Re-Designation of Guowei Zhan from an Executive Director to Non-Executive Director, Effective September 1, 2023

Broncus Holding Corporation to Report First Half, 2023 Results on Aug 29, 2023

Broncus Holding Corporation Completes the First Case of Registered Clinical Trials of Its Targeted Lung Denervation Radiofrequency Ablation System

Will Broncus Holding (HKG:2216) Spend Its Cash Wisely?

Consensus estimates of losses per share improve by 48%

Consensus revenue estimates fall by 36%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Companies Like Broncus Holding (HKG:2216) Are In A Position To Invest In Growth

An Intrinsic Calculation For Broncus Holding Corporation (HKG:2216) Suggests It's 47% Undervalued

Less than half of directors are independent

Broncus Holding Corporation Announces Zhejiang Medical Products Administration Approves Disposable Nebulizing Micro-Catheter for Endoscope for Marketing in China

Consensus forecasts updated

Analysts Just Slashed Their Broncus Holding Corporation (HKG:2216) EPS Numbers

First half 2022 earnings released: US$0.03 loss per share (vs US$0.19 loss in 1H 2021)

Broncus Holding Corporation Announces Board and Executive Changes

Broncus Holding Corporation to Report First Half, 2022 Results on Aug 30, 2022

Consensus EPS estimates fall by 16%

Broncus Holding Corporation Completes Surgeries on the First Group of Patients Using Its InterVapor, the Thermal Vapor Treatment System, After Approved for Marketing in China

Here's Why We're Not Too Worried About Broncus Holding's (HKG:2216) Cash Burn Situation

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Broncus Holding Corporation, Annual General Meeting, May 13, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2024

Broncus Holding Corporation Announces Resignation of Wen Hao Wang as Chief Financial Officer

Non Executive Director recently bought HK$390k worth of stock

Broncus Holding Corporation announces Enrollment for Registered Clinical Trials Successfully Completed for RF-II in China

Broncus Holding Corporation has completed an IPO in the amount of HKD 1.670939 billion.

Less than half of directors are independent

Estabilidad y crecimiento de los pagos

Rentabilidad por dividendo vs. Mercado

Pago de beneficios a los accionistas

Pago en efectivo a los accionistas

Descubre empresas que pagan buenos dividendos